Entera Bio Ltd. (ENTX) Bundle
An Overview of Entera Bio Ltd. (ENTX)
General Summary of Entera Bio Ltd. (ENTX)
Entera Bio Ltd. is a clinical-stage biopharmaceutical company that specializes in developing oral drug delivery systems for therapeutic proteins and peptides. Founded in 2015 and headquartered in Jerusalem, Israel, Entera Bio focuses on leveraging its proprietary N-Tab™ technology to enhance the bioavailability of medications traditionally administered via injection.
The company's lead product candidates include EB613, a treatment for osteoporosis, and EB612, aimed at metabolic bone diseases. As of 2024, Entera Bio has not yet generated significant revenue from product sales, but it has reported revenues of $99,000 for the nine months ended September 30, 2024, primarily from research services provided under a collaboration agreement.
Company's Financial Performance in the Latest Financial Reports
In the latest financial reporting period, Entera Bio Ltd. reported revenues of $42,000 for the three months ended September 30, 2024, a 100% increase compared to no revenue in the same period in 2023. For the nine months ended September 30, 2024, revenues totaled $99,000, also a 100% increase from zero in the same period in 2023.
The company's operating expenses for the three months ended September 30, 2024, were $3.02 million, up from $2.39 million in the same period in 2023, reflecting an increased investment in research and development and general administrative expenses. For the nine months ended September 30, 2024, the total operating loss was $7.25 million, compared to $6.93 million for the same period in 2023.
As of September 30, 2024, Entera Bio had an accumulated deficit of $111.57 million, with cash and cash equivalents amounting to $6.92 million. The company expects to continue incurring substantial losses as it advances its product candidates through development.
Introduction to Entera Bio as a Leader in the Industry
Entera Bio Ltd. is positioned as a leader in the biopharmaceutical sector, particularly in the oral delivery of therapeutic proteins and peptides. The company’s proprietary N-Tab™ technology has the potential to transform how patients receive medications that are typically injected, addressing significant market needs in drug delivery. The advancements in their lead products, EB613 and EB612, signify their commitment to innovation in the treatment of metabolic bone diseases.
As the company continues to progress through clinical trials, its strategic focus on enhancing drug delivery methods places it at the forefront of industry advancements. Investors and stakeholders are encouraged to explore further to understand the underlying factors contributing to Entera Bio's anticipated success in the biopharmaceutical landscape.
| Financial Metrics | Q3 2024 | Q3 2023 | YTD 2024 | YTD 2023 |
|---|---|---|---|---|
| Revenues | $42,000 | $0 | $99,000 | $0 |
| Operating Expenses | $3,021,000 | $2,386,000 | $7,257,000 | $6,928,000 |
| Net Loss | $3,021,000 | $2,379,000 | $7,183,000 | $6,894,000 |
| Cash and Cash Equivalents | $6,915,000 | |||
| Accumulated Deficit | $111,569,000 | |||
Mission Statement of Entera Bio Ltd. (ENTX)
Mission Statement of Entera Bio Ltd. (ENTX)
Entera Bio Ltd.'s mission statement articulates its commitment to advancing innovative oral drug delivery solutions, aiming to enhance the quality of life for patients with unmet medical needs. This mission serves as a guiding principle, aligning the company’s long-term strategic goals with its core values and operational objectives.
Core Components of the Mission Statement
1. Innovation in Oral Drug Delivery
At the heart of Entera Bio's mission is its focus on innovation, particularly in the realm of oral drug delivery technologies. The company leverages its proprietary N-Tab™ technology platform, which is designed to improve the bioavailability of therapeutic proteins and peptides. This innovative approach is critical as it addresses significant challenges in the pharmaceutical industry related to the efficacy of orally administered drugs.
2. Commitment to Patient-Centric Solutions
Entera Bio emphasizes a patient-centric approach, aiming to develop solutions that meet the specific needs of patients. This commitment is reflected in the company’s ongoing research and development efforts, particularly in areas such as osteoporosis and metabolic diseases. As of September 30, 2024, Entera Bio reported revenues of $99,000 attributed to research services, highlighting its involvement in practical applications that benefit patient outcomes.
3. Addressing Unmet Medical Needs
Entera Bio is dedicated to addressing unmet medical needs through its innovative product pipeline. The company is actively engaged in the development of its lead product candidates, EB613 and EB612, targeting conditions such as osteoporosis and metabolic disorders. As of September 30, 2024, Entera Bio had incurred significant operating losses amounting to $7.2 million for the nine months, underscoring the substantial investment required to bring these solutions to market.
| Financial Metrics | Q3 2024 | Q3 2023 | Change (%) |
|---|---|---|---|
| Revenues | $42,000 | $0 | 100% |
| Operating Loss | $3.0 million | $2.4 million | 25% |
| R&D Expenses | $1.5 million | $1.4 million | 8% |
| General & Admin Expenses | $1.5 million | $1.0 million | 50% |
With a focus on innovation, patient-centric solutions, and addressing unmet medical needs, Entera Bio Ltd.'s mission statement not only reflects its core values but also reinforces its commitment to advancing healthcare through groundbreaking research and development efforts. As of September 30, 2024, the company had accumulated a deficit of $111.6 million, indicating the ongoing challenges and investments required in its pursuit of these objectives.
Vision Statement of Entera Bio Ltd. (ENTX)
Vision Statement Overview
The vision statement of Entera Bio Ltd. (ENTX) as of 2024 focuses on the company's commitment to transforming the treatment landscape for patients with chronic diseases through innovative oral drug delivery technologies. This vision encapsulates the company’s goal of enhancing patient outcomes and improving quality of life through advanced therapeutic solutions.
Innovation in Drug Delivery
Entera Bio aims to lead the industry in developing oral formulations of therapeutic agents that traditionally require injection. The company is focused on its proprietary N-Tab™ technology, which enhances the bioavailability of drugs administered orally. This innovation is expected to significantly improve patient compliance and expand the accessibility of therapies.
Commitment to Patient-Centric Solutions
At the core of Entera Bio's vision is a strong commitment to patient-centric solutions. The company emphasizes the importance of understanding patient needs and preferences in the development of its products. By prioritizing patient feedback, Entera Bio aims to create therapies that not only treat diseases effectively but also fit seamlessly into patients’ lives.
Strategic Partnerships and Collaborations
To realize its vision, Entera Bio actively seeks strategic partnerships and collaborations with other biotech and pharmaceutical companies. These collaborations are aimed at accelerating the development of its product pipeline, including partnerships for clinical trials and commercialization efforts. As of September 30, 2024, Entera Bio has engaged in collaborations that have contributed to its research capabilities and market reach.
Financial Commitment to Research and Development
Entera Bio is committed to investing in research and development (R&D) to advance its product candidates. For the three months ended September 30, 2024, Entera Bio reported R&D expenses of $1.5 million, up from $1.4 million in the same period in 2023. The company’s total R&D expenses for the nine months ended September 30, 2024, were $3.3 million, showing a slight decrease from $3.5 million in the prior year. This investment underscores the company’s dedication to developing innovative therapies that align with its vision of improving patient care.
Market Position and Future Aspirations
Entera Bio's vision includes establishing a strong market position within the biopharmaceutical industry. The company aims to leverage its unique technology and growing pipeline of products to capture significant market share in the oral drug delivery sector. As of September 30, 2024, Entera Bio had cash and cash equivalents of $6.9 million, which it plans to utilize to fund ongoing operations and R&D. The company’s ability to secure additional funding will be critical to its future success and to achieving its vision of becoming a leader in innovative drug delivery solutions.
| Financial Metrics | Three Months Ended September 30, 2024 | Three Months Ended September 30, 2023 | Nine Months Ended September 30, 2024 | Nine Months Ended September 30, 2023 |
|---|---|---|---|---|
| Revenues | $42,000 | $0 | $99,000 | $0 |
| Cost of Revenues | $42,000 | $0 | $90,000 | $0 |
| R&D Expenses | $1.5 million | $1.4 million | $3.3 million | $3.5 million |
| Net Loss | $3.0 million | $2.4 million | $7.2 million | $6.9 million |
Long-Term Vision and Impact
Looking ahead, Entera Bio envisions a future where its innovative oral delivery systems significantly impact the treatment of chronic diseases, providing patients with more effective and convenient treatment options. The company is dedicated to advancing its technologies and expanding its therapeutic portfolio to fulfill this vision, ultimately aiming to enhance the lives of patients worldwide.
Core Values of Entera Bio Ltd. (ENTX)
Commitment to Innovation
Entera Bio Ltd. values innovation as a core principle, driving the development of its proprietary N-Tab™ technology platform. This commitment is reflected in the company's research and development (R&D) expenditures, which amounted to $3.3 million for the nine months ended September 30, 2024, down from $3.5 million in the same period of 2023.
The company is focused on advancing its product candidates, such as EB613 and EB612, through clinical trials. Notably, the R&D expenses for the three months ended September 30, 2024, reached $1.5 million, indicating a strategic investment in innovative solutions.
Integrity and Transparency
Integrity and transparency are fundamental to Entera Bio's operations, especially in its financial reporting and stakeholder communications. The company maintains high standards of disclosure, as seen in its quarterly financial reports, which detail revenues, operating expenses, and net losses. For the nine months ended September 30, 2024, Entera reported revenues of $99,000, a significant increase from $0 in the previous year.
The net loss for the same period was $7.2 million, reflecting ongoing investments in R&D and administrative expenses. This transparency enables investors and stakeholders to make informed decisions based on the company's financial health and strategic direction.
Collaboration and Teamwork
Collaboration is a core value that Entera Bio promotes within its workforce and through partnerships. As of September 30, 2024, the company employed 20 staff members, highlighting a small but focused team dedicated to research and development. The company actively collaborates with external partners, such as OPKO, for research initiatives related to GLP-2 and OXM.
Furthermore, Entera's engagement in material transfer and research project agreements demonstrates its commitment to teamwork, with revenues from such agreements amounting to $42,000 for the three months ended September 30, 2024.
Accountability
Accountability is a critical value that Entera Bio upholds through its governance and operational practices. The company has established a robust framework for financial management, ensuring that all expenditures align with its strategic goals. For the nine months ended September 30, 2024, general and administrative expenses were $4.0 million, up from $3.5 million in the previous year, reflecting increased investments in operational efficiency.
Entera's financial records show an accumulated deficit of $111.6 million, indicating the company's commitment to managing its financial health while pursuing long-term growth.
| Core Value | Description | Financial Commitment |
|---|---|---|
| Innovation | Focus on R&D and proprietary technology development | $3.3 million in R&D expenses (2024) |
| Integrity and Transparency | High standards of disclosure and reporting | $99,000 in revenues (2024) |
| Collaboration and Teamwork | Engagement with partners and a dedicated team | $42,000 from research agreements (2024) |
| Accountability | Robust financial management and governance | $4.0 million in administrative expenses (2024) |
Entera Bio Ltd. (ENTX) DCF Excel Template
5-Year Financial Model
40+ Charts & Metrics
DCF & Multiple Valuation
Free Email Support
Updated on 16 Nov 2024
Resources:
- Entera Bio Ltd. (ENTX) Financial Statements – Access the full quarterly financial statements for Q3 2024 to get an in-depth view of Entera Bio Ltd. (ENTX)' financial performance, including balance sheets, income statements, and cash flow statements.
- SEC Filings – View Entera Bio Ltd. (ENTX)' latest filings with the U.S. Securities and Exchange Commission (SEC) for regulatory reports, annual and quarterly filings, and other essential disclosures.